Deirdre Zander-Fox1,2,3,4,5,6, Lauren Villarosa7,8, Nicole O McPherson8,9,10. 1. Repromed, Dulwich South Australia, Australia. dzander@monashivfgroup.com. 2. Department of Bioengineering, University of South Australia, Adelaide, Australia. dzander@monashivfgroup.com. 3. Monash University, Clayton, Australia. dzander@monashivfgroup.com. 4. Monash IVF Group, Richmond, Victoria, Australia. dzander@monashivfgroup.com. 5. Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia. dzander@monashivfgroup.com. 6. School of Medicine, University of Adelaide, Adelaide, Australia. dzander@monashivfgroup.com. 7. Repromed, Dulwich South Australia, Australia. 8. Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia. 9. School of Medicine, University of Adelaide, Adelaide, Australia. 10. Freemasons Center for Male Health and Wellbeing, University of Adelaide, Adelaide, South Australia, Australia.
Abstract
PURPOSE: Different commercial human embryo culture mediums can alter embryo quality and change birthweight. One component that could be contributing to variations but is not widely investigated is human serum albumin (HSA). HSA plays a multitude of roles during embryo culture and is a carrier for molecules including lipids. It remains unclear if lipid composition of HSA varies among commercial products and its effects on embryo quality, implantation, and fetal outcomes are relatively unknown. METHODS: Utilizing a mouse model of embryo culture, we cultured zygotes until the blastocyst stage (72-h culture) in G1/G2 containing either Vitrolife HSA, Sage HSA, or Recombinant HSA at 10%. Blastocyst quality (development, total cell number, superoxide generation), blastocyst lipid content (neutral lipids, non-esterified fatty acids, phospholipids, and triglycerides), implantation, and fetal lengths and weights were assessed. Fatty acid quantification of HSA source was assessed by standard thin-layer chromatography. RESULTS: Sage HSA had the greatest fatty acid composition, with an eightfold increase in saturated fatty acids. This coincided with reduced blastocyst development, increased superoxide generation, neutral lipids and triglycerides levels of blastocysts, and decreased implantation rates (p < 0.05). Unexpectedly, while Recombinant HSA had the lowest overall lipids it had 70-fold increase in palmitoleic acid and the lowest fetal weights (p < 0.05). CONCLUSION: Indicates the importance of a balance between different types/amount of lipids, and an "optimal ratio" required for embryo and fetal development. Therefore, the lipid content of HSA should be considered when choosing a suitable HSA source for use in clinical IVF.
PURPOSE: Different commercial human embryo culture mediums can alter embryo quality and change birthweight. One component that could be contributing to variations but is not widely investigated is human serum albumin (HSA). HSA plays a multitude of roles during embryo culture and is a carrier for molecules including lipids. It remains unclear if lipid composition of HSA varies among commercial products and its effects on embryo quality, implantation, and fetal outcomes are relatively unknown. METHODS: Utilizing a mouse model of embryo culture, we cultured zygotes until the blastocyst stage (72-h culture) in G1/G2 containing either Vitrolife HSA, Sage HSA, or Recombinant HSA at 10%. Blastocyst quality (development, total cell number, superoxide generation), blastocyst lipid content (neutral lipids, non-esterified fatty acids, phospholipids, and triglycerides), implantation, and fetal lengths and weights were assessed. Fatty acid quantification of HSA source was assessed by standard thin-layer chromatography. RESULTS: Sage HSA had the greatest fatty acid composition, with an eightfold increase in saturated fatty acids. This coincided with reduced blastocyst development, increased superoxide generation, neutral lipids and triglycerides levels of blastocysts, and decreased implantation rates (p < 0.05). Unexpectedly, while Recombinant HSA had the lowest overall lipids it had 70-fold increase in palmitoleic acid and the lowest fetal weights (p < 0.05). CONCLUSION: Indicates the importance of a balance between different types/amount of lipids, and an "optimal ratio" required for embryo and fetal development. Therefore, the lipid content of HSA should be considered when choosing a suitable HSA source for use in clinical IVF.
Authors: Michelle Lane; Megan Mitchell; Kara S Cashman; Deanne Feil; Sarah Wakefield; Deirdre L Zander-Fox Journal: Reprod Fertil Dev Date: 2008 Impact factor: 2.311
Authors: M Tarahomi; F M Vaz; J P van Straalen; F A P Schrauwen; M van Wely; G Hamer; S Repping; S Mastenbroek Journal: Hum Reprod Date: 2019-08-01 Impact factor: 6.918
Authors: Dean E Morbeck; Rebecca L Krisher; Jason R Herrick; Nikola A Baumann; Dietrich Matern; Thomas Moyer Journal: Fertil Steril Date: 2014-07-04 Impact factor: 7.329
Authors: Veerle Van Hoeck; Roger G Sturmey; Pablo Bermejo-Alvarez; Dimitrios Rizos; Alfonso Gutierrez-Adan; Henry J Leese; Peter E J Bols; Jo L M R Leroy Journal: PLoS One Date: 2011-08-17 Impact factor: 3.240